Nick Goeden, Ph.D.
Founder, Chief Technology Officer
Nick Goeden co-founded Capsida Biotherapeutics and serves as Chief Technology Officer. Prior to co-founding Capsida, Dr. Goeden led a team developing the novel adeno-associated virus (AAV) engineering technology underlying Capsida’s biologically driven gene therapy platform. During his tenure as a postdoctoral fellow at Caltech, he developed high-throughput methods for screening combinatorial libraries to explore the AAV fitness landscape and engineered novel AAVs with high efficiency and specificity for the rodent and primate brain. During his Ph.D., Dr. Goeden developed a novel organ bioreactor to study real-time metabolomics in diseased states, exploring the relationship between gene expression and the pathophysiology of neurodevelopmental disorders.
Dr. Goeden holds a B.S. in biology from the Caltech and a Ph.D. in neuroscience from The University of Southern California.